Stephen J Kohut1, Peter A Fivel, Nancy K Mello. 1. Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA. Electronic address: skohut@mclean.harvard.edu.
Abstract
BACKGROUND: Lofexidine, an α2-adrenergic agonist, is being investigated as a treatment for reducing opioid withdrawal symptoms and blocking stress-induced relapse to cocaine taking. Opioid abusers are often polydrug abusers and cocaine is one frequent drug of choice. However, relatively little is known about lofexidine interactions with cocaine. The present study investigated the effects of acute and chronic treatment with lofexidine in a pre-clinical model of cocaine self-administration. METHODS: Male rhesus monkeys were trained to respond for food (1g) and cocaine (0.01 mg/kg/injection) under a fixed ratio 30 (FR30) or a second order FR2 (VR16:S) schedule of reinforcement. Systematic observations of behavior were conducted during and after chronic treatment with lofexidine. RESULTS: Acute treatment with lofexidine (0.1 or 0.32 mg/kg, IM) significantly reduced cocaine self-administration but responding for food was less effected. In contrast, chronic treatment (7-10 days) with lofexidine (0.1-0.32 mg/kg/h, IV) produced a leftward shift in the cocaine self-administration dose-effect curve, but had no effect on food-maintained responding. Lofexidine did not produce any observable side effects during or after treatment. CONCLUSIONS: Lofexidine potentiated cocaine's reinforcing effects during chronic treatment. These data suggest that it is unlikely to be effective as a cocaine abuse medication and could enhance risk for cocaine abuse in polydrug abusers.
BACKGROUND:Lofexidine, an α2-adrenergic agonist, is being investigated as a treatment for reducing opioid withdrawal symptoms and blocking stress-induced relapse to cocaine taking. Opioid abusers are often polydrug abusers and cocaine is one frequent drug of choice. However, relatively little is known about lofexidine interactions with cocaine. The present study investigated the effects of acute and chronic treatment with lofexidine in a pre-clinical model of cocaine self-administration. METHODS: Male rhesus monkeys were trained to respond for food (1g) and cocaine (0.01 mg/kg/injection) under a fixed ratio 30 (FR30) or a second order FR2 (VR16:S) schedule of reinforcement. Systematic observations of behavior were conducted during and after chronic treatment with lofexidine. RESULTS: Acute treatment with lofexidine (0.1 or 0.32 mg/kg, IM) significantly reduced cocaine self-administration but responding for food was less effected. In contrast, chronic treatment (7-10 days) with lofexidine (0.1-0.32 mg/kg/h, IV) produced a leftward shift in the cocaine self-administration dose-effect curve, but had no effect on food-maintained responding. Lofexidine did not produce any observable side effects during or after treatment. CONCLUSIONS:Lofexidine potentiated cocaine's reinforcing effects during chronic treatment. These data suggest that it is unlikely to be effective as a cocaine abuse medication and could enhance risk for cocaine abuse in polydrug abusers.
Authors: Jesse R Schank; Rossella Ventura; Stefano Puglisi-Allegra; Antonio Alcaro; Charlene D Cole; L Cameron Liles; Philip Seeman; David Weinshenker Journal: Neuropsychopharmacology Date: 2005-12-14 Impact factor: 7.853
Authors: Elmer Yu; Karen Miotto; Evaristo Akerele; Charles P O'Brien; Walter Ling; Herbert Kleber; Marian W Fischman; Ahmed Elkashef; Barbara H Herman; Abeer M Al-Ghananeem Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: R De La Garza; G P Galloway; T F Newton; J Mendelson; C N Haile; E Dib; R Y Hawkins; C-Y A Chen; J J Mahoney; J Mojsiak; G Lao; A Anderson; R Kahn Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2013-12-04 Impact factor: 5.067
Authors: Stephen J Kohut; David S Jacobs; Richard B Rothman; John S Partilla; Jack Bergman; Bruce E Blough Journal: Psychopharmacology (Berl) Date: 2017-09-09 Impact factor: 4.530
Authors: Fernando B de Moura; Alexander Sherwood; Thomas E Prisinzano; Carol A Paronis; Jack Bergman; Stephen J Kohut Journal: Pharmacol Biochem Behav Date: 2021-01-12 Impact factor: 3.533